Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%
Market cap
$2.2B
P/E
12.2×
Fwd P/E
9.4×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 5 7

+8 more TTM periods

ROE
20.46% 17.86% 20.75% 25.93%
ROA
14.61% 12.51% 13.98% 17.38%
ROIC
29.70% 27.66% 50.40% 42.60%
Return on Tangible Assets
31.24% 25.93% 24.23% 30.10%
Average Days of Receivables
42.21 43.93 40.68 44.48
Free Cash Flow per Share
6.13 5.91 6.05 5.16
Free Cash Flow
355.08 341.97 347.89 296.89
Other line items

Show all line items

Columns are period end dates